p-8

Laminin B1 octapeptide P-8 is a synthetic laminin B1 chain octapeptide with laminin receptor binding ability.

WEHI-P8 is an orally active inhibitor targeting the coronavirus papain-like protease (PLpro). It inhibits SARS-CoV-2 PLpro with an IC50 of 12 nM and demonstrates excellent cellular activity with an EC50 of 298 nM. Additionally, WEHI-P8 has protective effects in mice against prolonged lung and brain symptoms caused by SARS-CoV-2. This compound is applicable for research on post-COVID-19 syndrome.

TTP-8307 is an antiviral compound that inhibits the replication of rhinoviruses and enteroviruses, and inhibits coxsackievirus B3 and poliovirus by interfering with viral RNA synthesis.TTP-8307 can be used in the study of viral infections.

GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2].

CP-810123 is a new alpha 7 nAChR agonist for the treatment of cognitive impairment associated with psychiatric or neurological disorders such as schizophrenia and Alzheimer's disease.

CP-866087 is a novel, potent and selective mu-opioid receptor antagonist for the study of female sexual dysfunction.

CP-809101 hydrochloride is a potent and selective 5-HT2C receptor agonist with pEC50 values of 9.96 for human 5-HT2C, 7.19 for 5-HT2B, and 6.81 for 5-HT2A receptors.

NSP-805 is a potent and selective inhibitor of guinea pig cardiac phosphodiesterase 3 (PDE3).

SP-8356 is a potent, orally active inhibitor of cluster of differentiation 147 (CD147),and is an anti-inflammatory synthetic verbenone derivative, with anti-atherosclerotic effects.

SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.

ASP8731 is a selective inhibitor of BACH1 that prevents inflammation and vascular occlusion, and induces fetal hemoglobin in sickle cell disease.

KP-81 is a structurally complex aromatic compound used in organic synthesis and drug design.

GHP-88309 is an orally active, broad-spectrum anti-paramyxovirus agent that targets viral polymerase, interrupting viral RNA synthesis. It effectively inhibits respiratory syncytial virus (RSV), measles virus (MeV), and canine distemper virus (CDV) with an EC50 of 0.06-1.2 μM. In mouse models, GHP-88309 demonstrates significant anti-infective activity.

CP-865569 is a CCR1 antagonist useful in the research of inflammatory and autoimmune diseases, including conditions such as rheumatoid arthritis and multiple sclerosis.

LYP-8 is a potent NAMPT degrader that achieves a maximum degradation rate of 97% in NAMPT within SKOV-3 cells at a concentration of 0.5 μM. LYP-8 also demonstrates anticancer activity both in vitro and in vivo.

BRP-821 is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 value of 0.4 nM. It is utilized in research related to inflammation, cardiovascular, metabolic, and neurological disorders.

CP-800569 is an orally active inhibitor of cholesteryl ester transfer protein (CETP). It effectively reduces low-density lipoprotein and postprandial triglycerides while increasing high-density lipoprotein. CP-800569 is applicable in the study of metabolic diseases.

GHP-88310 (EIDD-3608) is a potent, orally active inhibitor of orthoparamyxovirus polymerases. It exhibits strong activity against Human Parainfluenza Virus Type 3 (HPIV3) and related respiratory viruses, as well as Measles Virus (MeV) and associated measles pathogens. GHP-88310 has demonstrated effectiveness in both the canine distemper virus (CDV) ferret model and the HPIV3 cotton rat model. This compound is useful for researching orthoparamyxovirus-related diseases.

XMU-MP-8 (SKPer1) is a potent molecular glue degrader that targets the oncogenic protein SKP2. It interacts with the F-box domain of SKP2 (Kd≈ 36 μM) and the N-terminal TPR domain of the E3 ligase STUB1 (Kd≈ 2.5 μM), leading to the formation of a stable SKP2-SKPer1-STUB1 ternary complex (Kd≈ 8.9 nM). This interaction triggers the ubiquitination and proteasomal degradation of SKP2. XMU-MP-8 selectively eradicates cancer cells expressing SKP2 and exhibits notable tumor-suppressive effects in vivo along with a favorable safety profile. It is applicable in research on cancers such as non-small cell lung adenocarcinoma (NSCLC) and prostate adenocarcinoma.

cGMP-dependent protein kinase (PKG) inhibitor

CEP-8983 is a PARP inhibitor potentially for the treatment of solid tumours.

ASP8497 is a potent, long-acting DPP-IV inhibitor that improves glucose tolerance by elevating GLP-1 levels in a glucose-dependent insulin-stimulating manner. The compound is used as a therapeutic agent for impaired glucose tolerance and type 2 diabetes.

CP-85958 is a cysteinyl leukotriene antagonist.

CP-8668 is an orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzoindolone skeleton.